tbuckley/cabot-search huggingface dataset:
Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor
Authors: Katherine G. MacDonald, Romy E. Hoeppli, Qing Huang, Jana Gillies, Dan S. Luciani, Paul C. Orban, Raewyn Broady, Megan K. Levings
Journal: Journal of Clinical Investigation (2016)

Adoptive immunotherapy with regulatory T cells (Tregs) is a promising treatment for allograft rejection and graft-versus-host disease (GVHD). Emerging data indicate that, compared with polyclonal Tregs, disease-relevant antigen-specific Tregs may have numerous advantages, such as a need for fewer cells and reduced risk of nonspecific immune suppression. Current methods to generate alloantigen-specific Tregs rely on expansion with allogeneic antigen-presenting cells, which requires access to donor and recipient cells and multiple MHC mismatches. The successful use of chimeric antigen receptors (CARs) for the generation of antigen-specific effector T cells suggests that a similar approach could be used to generate alloantigen-specific Tregs. Here, we have described the creation of an HLA-A2-specific CAR (A2-CAR) and its application in the generation of alloantigen-specific human Tregs. In vitro, A2-CAR-expressing Tregs maintained their expected phenotype and suppressive function before, during, and after A2-CAR-mediated stimulation. In mouse models, human A2-CAR-expressing Tregs were superior to Tregs expressing an irrelevant CAR at preventing xenogeneic GVHD caused by HLA-A2+ T cells. Together, our results demonstrate that use of CAR technology to generate potent, functional, and stable alloantigen-specific human Tregs markedly enhances their therapeutic potential in transplantation and sets the stage for using this approach for making antigen-specific Tregs for therapy of multiple diseases.
In Vitro Inhibition of Tritiated Thymidine Uptake in Morris Hepatoma Cells by Normal Rat Liver Extract: A Possible Liver Chalone 2
Authors: C. Y. Kuo, T. J. Yoo
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article In Vitro Inhibition of Tritiated Thymidine Uptake in Morris Hepatoma Cells by Normal Rat Liver Extract: A Possible Liver Chalone Get access C. Y. Kuo, C. Y. Kuo 3Department of Medicine, University of Iowa and Veterans Administration Hospitals, Iowa City, Iowa 52240 Search for other works by this author on: Oxford Academic PubMed Google Scholar T. J. Yoo T. J. Yoo 4 3Department of Medicine, University of Iowa and Veterans Administration Hospitals, Iowa City, Iowa 52240 5We thank Dr. Daryl K. Granner and Dr. Carl S. Vestling, University of Iowa, for their critical comments. We appreciate the editorial assistance of Ms. Lynn Cook and Mr. Charles L. Egleston. 4Address reprint requests to Dr. Yoo. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 6, December 1977, Pages 1691–1695, https://doi.org/10.1093/jnci/59.6.1691 Published: 01 December 1977 Article history Received: 22 March 1977 Accepted: 05 July 1977 Published: 01 December 1977
Cell-Mediated Immune Response to Simian Oncornavirus Antigens in Pregnant Women 2
Authors: L. Thiry, S. Sprecher-Goldberger, M. Bossens, F. Neuray
Journal: JNCI Journal of the National Cancer Institute (1978)

Tritiated thymidine incorporation into lymphocytes of 118 adult women was studied in the presence of mitomycin C-treated cells prepared from cell lines continuously producing Mason-Pfizer monkey virus (MPMV), baboon C-particle virus, or simian sarcoma virus (SSV) and in the presence of control cell lines documented for the absence of oncornaviruses. At the end of pregnancy, women who had 5-9 pregnancies showed a high frequency (53%) of specific positive responses to cells with MPMV antigens. The frequencies were 15% for pregnant women with smaller numbers of pregnancies and 3% for nonpregnant women with similar numbers of previous pregnancies as in the pregnancy group. None of these nonpregnant women had lymphocytes responding to stimulation by baboon C-virus antigens, but positive responses were obtained in 20 and 16% of the pregnant groups, respectively. No correlation was found between responses to MPMV or baboon C-virus antigens. Of 48 women (35 pregnant, 13 nonpregnant) who were tested for lymphocyte responses to SSV antigens, only 2 showed a positive response. The results indicated that two distinct antigens, related to MPMV and to baboon C-virus, may be expressed during pregnancy and may then induce a transient cell-mediated response.
Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314).
Authors: R. Hofheinz, L. Mineur, R. Greil, C. Kohne, H. Letocha, J. Thaler, E. Fernebro, E. Gamelin, L. DeCosta, M. Karthaus
Journal: Journal of Clinical Oncology (2010)

3545 Background: Pmab, a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is approved in Europe as monotherapy for pts with chemotherapy-refractory, EGFR-expressing, KRAS wild-type (WT) mCRC. Methods: Ptsreceived pmab (6 mg/kg) and FOLFIRI every 2 weeks. Eligibility criteria included histologically confirmed mCRC (no prior systemic treatment for metastatic disease), ECOG PS 0–2 and availability of tumor tissue for biomarker analysis. The primary endpoint was objective response rate and secondary endpoints included progression-free survival and safety. All analyses are descriptive, this abstract discusses resections. Results: A total of 154 pts were enrolled. At time of primary analysis (June 09), KRAS evaluable samples were available for 94% (n = 145) of pts: 86 (59%) pts had KRAS WT tumors and 59 (41%) pts had KRAS mutant (MT) tumors. Demographics in the primary analysis set (all KRAS evaluable pts) by KRAS WT and MT were: 78%/54% male; median age (range) 63.5 years (21–84)/65.0 years (37-80); ECOG PS 0-1 95%/93%. Response rate in the KRAS WT group was 56% vs 38% in the MT group and median progression-free survival was 8.9 months vs 7.2 months. Resection rate was 15% (95% CI 8.3%, 24.5%) and 7% (95% CI 1.9%, 16.5%), and the majority of pts that underwent surgery had liver only mets 12 (92%) and 2 (50%), in the KRAS WT and MT groups respectively. One pt in the KRAS WT group had surgery for skin lesion mets and in the KRAS MT group, one pt underwent surgery for ovary and colon mets and another for lung mets. Complete removal was achieved in 8% (95% CI 3.3%, 16.1%) of pts in the KRAS WT group and 5% (95% CI 1.1%, 14.2%) in the KRAS MT group. Adverse events (AEs) were in line with previously reported data and KRAS status did not appear to influence incidence of these AEs. There were 3 treatment-related grade 5 events (haematemesis and rectal haemorrhage in the WT group and vena cava thrombosis in the MT group). Conclusions: Pmab combined with FOLFIRI in the first-line setting appears to be a well-tolerated regimen. These data suggest that pmab may increase incidence of resection in the WT group versus MT group. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen Amgen Amgen Amgen Amgen
Selective Induction of Melanomas in Gerbils (&lt;italic&gt;Meriones unguiculatus&lt;/italic&gt;) Following Postnatal Administration of &lt;italic&gt;N&lt;/italic&gt;-Ethyl-&lt;italic&gt;N&lt;/italic&gt;-nitrosourea&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: P. Kleihues, J. Bücheler, U. N. Riede
Journal: JNCI Journal of the National Cancer Institute (1978)

Following a single ip injection (50 mg/kg) of N-ethyl-N-nitrosourea (ENU) on postnatal day 7 or 20, 9 of 21 gerbils (43%) developed a total of 15 cutaneous melanomas. The mean survival time of tumor-bearing animals was 909 +/- 212 (SD) days. Neoplasms were preferentially located at sites with little hair and with high content of pigment cells (feet, ears, tail, or snout). Histologic studies on newborn gerbils indicated that ENU-induced malignant transformation occurred in differentiated melanocytes rather than in precursor cells of the neural crest.
Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease
Authors: Maarten J. G. Leening, Jarett D. Berry, Norrina B. Allen
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Premonitory urges in Tourette's syndrome
Authors: J F Leckman, D E Walker, D J Cohen
Journal: American Journal of Psychiatry (1993)

Tourette's syndrome traditionally has been viewed as a hyperkinetic movement disorder characterized by involuntary motor and phonic tics. Many patients, however, describe their tics as a voluntary response to premonitory urges. This cross-sectional study evaluated premonitory urges and related phenomena in subjects with tic disorders.A total of 135 subjects with tic disorders, aged 8 to 71 years, completed a questionnaire concerning their current and past tic symptoms. Subjects were asked to describe and, if possible, localize their premonitory urges. The Yale Global Tic Severity Scale was used to assess current tic severity. The method of case finding does not provide prevalence data for premonitory urges.Ninety-three percent of the subjects reported premonitory urges. Anatomical regions with the greatest density of urges were the palms, shoulders, midline abdomen, and throat. Eighty-four percent of the subjects reported that tics were associated with a feeling of relief. A substantial majority (92%) also indicated that their tics were either fully or partially a voluntary response to the premonitory urges.While epidemiological studies of tic disorders have yet to incorporate questions concerning premonitory urges, these results suggest that such urges may be commonplace in adolescent and adult subjects with tic disorders. These results challenge the conventional wisdom that tic behaviors are wholly involuntary in character. They also implicate brain regions involved in the processing of sensorimotor information in the pathobiology of tic disorders.
Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates
Authors: Iftikhar J. Kullo, Hayan Jouni, Erin E. Austin, Sherry-Ann Brown, Teresa M. Kruisselbrink, Iyad N. Isseh, Raad A. Haddad, Tariq S. Marroush, Khader Shameer, Janet E. Olson, Ulrich Broeckel, Robert C. Green, Daniel J. Schaid, Victor M. Montori, Kent R. Bailey
Journal: Circulation (2016)

Background— Whether knowledge of genetic risk for coronary heart disease (CHD) affects health-related outcomes is unknown. We investigated whether incorporating a genetic risk score (GRS) in CHD risk estimates lowers low-density lipoprotein cholesterol (LDL-C) levels. Methods and Results— Participants (n=203, 45–65 years of age, at intermediate risk for CHD, and not on statins) were randomly assigned to receive their 10-year probability of CHD based either on a conventional risk score (CRS) or CRS + GRS ( + GRS). Participants in the + GRS group were stratified as having high or average/low GRS. Risk was disclosed by a genetic counselor followed by shared decision making regarding statin therapy with a physician. We compared the primary end point of LDL-C levels at 6 months and assessed whether any differences were attributable to changes in dietary fat intake, physical activity levels, or statin use. Participants (mean age, 59.4±5 years; 48% men; mean 10-year CHD risk, 8.5±4.1%) were allocated to receive either CRS (n=100) or + GRS (n=103). At the end of the study period, the + GRS group had a lower LDL-C than the CRS group (96.5±32.7 versus 105.9±33.3 mg/dL; P =0.04). Participants with high GRS had lower LDL-C levels (92.3±32.9 mg/dL) than CRS participants ( P =0.02) but not participants with low GRS (100.9±32.2 mg/dL; P =0.18). Statins were initiated more often in the + GRS group than in the CRS group (39% versus 22%, P &lt;0.01). No significant differences in dietary fat intake and physical activity levels were noted. Conclusions— Disclosure of CHD risk estimates that incorporated genetic risk information led to lower LDL-C levels than disclosure of CHD risk based on conventional risk factors alone. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01936675.
Soehendra stent retriever – a useful device for pancreatic pseudocyst drainage
Authors: Vera Costa Santos, Nuno Nunes, Filipa Ávila, Paulo Massinha, Ana Rego, José Pereira, Nuno Paz, Maria Duarte
Journal: Endoscopy (2016)

A 52-year-old patient with chronic pancreatitis was admitted for drainage of two symptomatic pancreatic pseudocysts. Endoscopic ultrasonography (EUS) showed pseudocysts in the pancreatic body and head of 50 × 40 mm and 30 × 20 mm in size, respectively.
Intravenous ghrelin for cancer-related anorexia/cachexia: A randomized, placebo-controlled, double-blind, double cross-over phase I/II study
Authors: F. Strasser, T. Lutz, B. Thürlimann, M. Mäder, D. Büche, M. Brändle, R. Von Moos, M. Tschöp, R. Demmer, T. Cerny
Journal: Journal of Clinical Oncology (2006)

8619 Background: Ghrelin is a natural hormone with stimulatory effects on appetite and body weight. We assessed safety, tolerability, pharmacokinetics, and preliminary efficacy of intravenous ghrelin in patients (pts) with cancer-related anorexia/cachexia. Methods: In a cross-over study 21 pts (median age 68 [44, 79]) were randomized for ghrelin (Merck Biosciences, Switzerland) given over 60 min before lunch or placebo on d1 and d8, or d4 and d11. Ten pts received low dose ghrelin (LD) 2mcg/kg, 11 pts high dose ghrelin (HD) 8mcg/kg. Safety and tolerability were assessed using CTC-Toxicity Criteria, cardiac examination, tumour measurement, and IGF-1. Pts preference for ghrelin or placebo was assessed at d8 and d17/18. Nutritional intake of lunch at treatment days (NIL) was measured in the hospital and thereafter daily by pts. Eating-related symptoms and blood levels of hormones were monitored during treatment days. Results: Adverse events possible or probable related to study drug, including 1 SAE (apoplectiform deafness, placebo), did not differ between ghrelin and placebo in pts on LD (7 vs. 14) and HD (19 vs. 13). Of 8 pts with SD at study entry, 1 had PD, 1 dropped out, and 6 pts remained SD during study. Of 12 pts with PD at study entry, 1 remained PD, 10 were SD, and 1 dropped out. 1 pat with PR at study entry had SD. Ghrelin treatment was preferred at d8 by 8/10 pts of LD and 9/11 of HD, and at d17/18 by 6/9 pts of LD and 6/10 of HD. Variability of nutritional intake and eating-related symptoms were high. They did overall not statistically differ between ghrelin (LD, HD) and placebo. At study start NIL was 642 kcal (SD 284) for LD and 424 (196) for HD. Weight remained unchanged. Total ghrelin levels were higher (p&lt;0.05) for HD at d17/18 (3580pg/ml) than study start (990), not for LD (950/1000). Active ghrelin, GH, or IGF-1 did not increase at d17/18 compared to study start. Conclusions: Ghrelin is well tolerated and safe in pts with far advanced cancer and anorexia/cachexia. More patients preferred ghrelin than placebo, without significant changes in nutritional intake or symptoms. Higher levels of total ghrelin at study end may suggest carry-over effects. Further research will explore schedule and dose modifications and mechanisms of ghrelin resistance. [Table: see text]
Age- and Sex-Related Differences in Antibody Formation And Blastogenic Responsiveness of Splenocytes From RIII Mice Developing Virus-Induced Mammary Adenocarcinoma&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: S Specter, H Friedman
Journal: JNCI Journal of the National Cancer Institute (1981)

Inbred RIII mice, known to be infected neonatally with murine mammary tumor virus so that females develop mammary adenocarcinoma by 12-15 months of age, were examined with regard to antisheep red blood cell antibody responses at the cellular level. Female mice, 3-11 months old, compared to male mice of the same ages had consistent and significant depression of the antibody response of their splenocytes. Furthermore, female mice with adenocarcinoma showed an even greater depression of the antibody response. Spleen sizes were consistently increased in females as compared to those of male mice throughout the first year of life. The blastogenic responsiveness of the splenocytes to the B-cell mitogen Escherichia coli lipopolysaccharide and the T-cell mitogen phytohemagglutinin-P was not significantly different between male and female mice during the same periods, although the responses of the older tumor-bearing female mice to phytohemagglutinin-P were lower than those of non-tumor-bearing female mice. A complex relationship between age, sex, and immune responsiveness was evident in these mammary tumor virus-infected mice, which made it difficult to attribute a specific immune event to emergence of the mammary adenocarcinomas in the female as compared to male mice.
MRI Survey In Transfusion-Dependent and Non-Transfusion-Dependent MDS Patients
Authors: Alessia Pepe, Antonella Meloni, Giancarlo Carulli, Esther Natalie Oliva, Francesco Arcioni, Sergio Storti, Patrizia Toia, Stefania Renne, Gennaro Restaino, Cristina Salvatori, Massimo Lombardi, Michele Rizzo
Journal: Blood (2013)
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Authors: O. Gluz, C. Liedtke, J. Huober, H. Peyro-Saint-Paul, R.E. Kates, H.H. Kreipe, A. Hartmann, E. Pelz, R. Erber, S. Mohrmann, V. Möbus, D. Augustin, G. Hoffmann, C. Thomssen, F. Jänicke, M. Kiechle, D. Wallwiener, W. Kuhn, U. Nitz, N. Harbeck
Journal: Annals of Oncology (2016)
Giant Pulmonary Artery Aneurysm in a Patient With Marfan Syndrome and Pulmonary Hypertension
Authors: Peter Chiu, Mallory Irons, Matt van de Rijn, David. H. Liang, D. Craig Miller
Journal: Circulation (2016)

defined. 2,3We present a case of giant pulmonary artery aneurysm (PAA) in a patient with pulmonary hypertension (PH) and connective tissue disorder.
Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995
Authors: Z. Neskovic-Konstantinovic, M. Nooij, H. Khaled, B. De Valk, J. Vermorken, M. Welnicka-Jaskiewicz, M. Piccart, S. Marreaud, J. Bogaerts, D. Cameron
Journal: Journal of Clinical Oncology (2007)

1040 Background: Safety and efficacy of classical CMF combined with 3-weekly Trastuzumab (T), followed by T alone in metastatic breast cancer (MBC). Methods: Patients (pts) with previously treated MBC were enrolled into a Phase II study of T (4 mg/kg then by 2 mg/kg) IV weekly plus CMF, Bonadonna regimen, for a maximum of 8 cycles (cy), followed by T alone (6 mg/kg) IV 3 weekly. Entry criteria included HER2 overexpression, limited anthracycline (A) exposure, normal baseline LVEF and measurable disease (RECIST). Cardiac endpoints were defined as: symptomatic CHF or LVEF drop by ≥ 15% from baseline or to ≥ 5% below lower limit. Results: The trial was closed to recruitment in January 2006, 12 pts are still on treatment. Seventy one pts were entered with a median age of 54 (range 31–75). Forty-one pts had prior CT (32 A), of which 26 adjuvant, 6 MBC, and 9 both adjuvant and MBC. Median PS was 0, 52 pts had visceral disease with a median interval from diagnosis to first relapse of 33.4 months (mo). Out of 70 pts receiving T+CMF (33 pts with 8 cy), 42 continued with T alone for a median duration of 7 cy. Eleven pts discontinued treatment for toxicity (9 on T+CMF, 2 on T alone). To date, the overall response rate is 55% (31/56 pts): 55% (23/42) 1st line; 57% (8/14) 2nd line. An independent review of responses is on-going. Median time to response was 2 mo, median duration of response was 8.3 mo and the median progression free survival was 9.2 mo. The most common grade 3–4 toxicity was neutropenia (53 %). Fourteen pts had cardiac toxicities, one NYHA grade 2 CHF, 6 pts with a drop in LVEF of 15% from baseline after a median of 3 mo of treatment, 9 pts with a drop in LVEF of 5% below LLN, after a median of 8 mo of treatment. The other toxicities included one grade 3 arrhythmia, two grade 3 hypertension, one grade 2 SVT, one grade 3 thrombosis, and one grade 2 dyspnea. One pt previously exposed to A had NYHA grade 4 CHF one year after treatment discontinuation. Conclusions: Combination of T+CMF regimen is feasible treatment for HER2+ MBC patients. The safety profile was acceptable, with cardiac toxicity and neutropenia within previously reported range. Drops in LVEF were mostly asymptomatic irrespective of previous exposure to A. Preliminary response data confirm good efficacy of CMF+T in MBC patients. [Table: see text]